Andrew Callos Sells 8,542 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Andrew Callos sold 8,542 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $62.15, for a total value of $530,885.30. Following the completion of the transaction, the executive vice president owned 71,573 shares of the company’s stock, valued at $4,448,261.95. The trade was a 10.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Andrew Callos also recently made the following trade(s):

• On Wednesday, March 18th, Andrew Callos sold 1,930 shares of Cytokinetics stock. The stock was sold at an average price of $62.07, for a total transaction of $119,795.10.
• On Monday, March 16th, Andrew Callos sold 1,709 shares of Cytokinetics stock. The stock was sold at an average price of $61.03, for a total transaction of $104,300.27.
• On Monday, March 9th, Andrew Callos sold 2,582 shares of Cytokinetics stock. The shares were sold at an average price of $60.72, for a total transaction of $156,779.04.
• On Thursday, March 5th, Andrew Callos sold 26,000 shares of Cytokinetics stock. The shares were sold at an average price of $61.87, for a total transaction of $1,608,620.00.
• On Thursday, February 5th, Andrew Callos sold 15,000 shares of Cytokinetics stock. The shares were sold at an average price of $61.93, for a total transaction of $928,950.00.
• On Monday, February 2nd, Andrew Callos sold 886 shares of Cytokinetics stock. The stock was sold at an average price of $62.10, for a total transaction of $55,020.60.
• On Monday, January 5th, Andrew Callos sold 15,000 shares of Cytokinetics stock. The stock was sold at an average price of $60.28, for a total transaction of $904,200.00.
• On Friday, January 2nd, Andrew Callos sold 1,798 shares of Cytokinetics stock. The shares were sold at an average price of $62.62, for a total transaction of $112,590.76.
• On Monday, December 29th, Andrew Callos sold 1,809 shares of Cytokinetics stock. The shares were sold at an average price of $62.44, for a total transaction of $112,953.96.

Cytokinetics Trading Up 1.2%

CYTK stock opened at $62.95 on Friday. The firm has a 50 day moving average of $63.79 and a 200-day moving average of $60.95. The company has a market cap of $7.75 billion, a price-to-earnings ratio of -9.64 and a beta of 0.56. Cytokinetics, Incorporated has a 12-month low of $29.31 and a 12-month high of $70.98.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.02). The company had revenue of $17.76 million during the quarter, compared to analyst estimates of $8.02 million. During the same quarter in the prior year, the company posted ($1.26) EPS. Cytokinetics’s revenue for the quarter was up 4.9% on a year-over-year basis. Sell-side analysts forecast that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on CYTK shares. The Goldman Sachs Group set a $95.00 price target on Cytokinetics and gave the company a “buy” rating in a research report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cytokinetics in a research report on Wednesday, January 21st. Citigroup reissued a “market outperform” rating on shares of Cytokinetics in a research note on Monday, December 22nd. Royal Bank Of Canada raised their target price on shares of Cytokinetics from $95.00 to $101.00 and gave the company an “outperform” rating in a report on Friday, February 20th. Finally, Robert W. Baird set a $84.00 target price on shares of Cytokinetics in a research report on Tuesday, March 10th. Seventeen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.89.

Key Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Mizuho raised its price target to $100 and kept an “outperform” rating, implying meaningful upside vs. the current share price — a catalyst for momentum buying. Mizuho raises target to $100
• Positive Sentiment: JPMorgan raised its target to $75 and maintained an overweight stance, adding institutional analyst support that can attract fund flows. JPMorgan raises target to $75
• Positive Sentiment: Large institutional holders (e.g., Vanguard, State Street) have been increasing positions, which supports longer‑term demand and underpins current price strength. Institutional holdings update
• Neutral Sentiment: Cytokinetics granted inducement awards (8,628 options and 5,719 RSUs) to five new hires under Nasdaq Rule 5635(c)(4); standard hiring comp — modest future dilution but intended to secure talent. Inducement grants
• Neutral Sentiment: Latest quarter showed a slight EPS miss but a revenue beat — mixed fundamentals that appear secondary to the recent analyst target moves in driving sentiment. Earnings recap
• Neutral Sentiment: Reported short‑interest data for March appears inconsistent/empty and is not a clear near‑term signal (days‑to‑cover shown as 0.0), so treat that item as noise until clarified by exchanges.
• Negative Sentiment: Significant insider selling: CEO Robert Blum sold ~36,601 shares (~$2.27M) and multiple EVPs sold large blocks across March. Large, clustered insider disposals can create short‑term selling pressure or be interpreted as diversification — worth monitoring for follow‑through. Insider selling details

Hedge Funds Weigh In On Cytokinetics

A number of institutional investors have recently made changes to their positions in CYTK. Bank of Montreal Can lifted its position in shares of Cytokinetics by 1.2% in the fourth quarter. Bank of Montreal Can now owns 13,292 shares of the biopharmaceutical company’s stock valued at $845,000 after acquiring an additional 160 shares in the last quarter. Kennedy Capital Management LLC increased its position in Cytokinetics by 1.2% during the 4th quarter. Kennedy Capital Management LLC now owns 13,183 shares of the biopharmaceutical company’s stock worth $838,000 after purchasing an additional 162 shares in the last quarter. UMB Bank n.a. raised its stake in Cytokinetics by 10.6% in the 3rd quarter. UMB Bank n.a. now owns 1,762 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 169 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in Cytokinetics by 46.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 171 shares during the last quarter. Finally, Vident Advisory LLC lifted its holdings in Cytokinetics by 1.4% in the 4th quarter. Vident Advisory LLC now owns 16,455 shares of the biopharmaceutical company’s stock valued at $1,046,000 after purchasing an additional 234 shares in the last quarter.

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.